Databricks acquires spreadsheet startup Row Zero to expand the capabilities of its AI coworker Genie; Row Zero raised a $10M seed led by IA Ventures last year
THE SO WHAT
Databricks is pulling the spreadsheet directly into its AI coworker, collapsing the gap between analysts’ native tool and the lakehouse. If your data team still lives in Excel or Sheets, expect pressure to standardize on AI-native, columnar spreadsheets tied to your warehouse rather than bolting AI onto legacy files.
READ THE SOURCE
MORE FROM THE WIRE
Startups & VentureAdarx Pharmaceuticals Raises $446.3 Million in Upsized US IPO
A $446.3M upsized IPO for a late-stage gene therapy developer is another data point that public markets will still pay for deep science with clear clinical paths. If you’re building in therapeutics or platform biotech, this supports a financing path that blends non-dilutive partnerships with eventual public capital rather than perpetual private rounds.
Startups & VentureDocuments: Jeff Bezos has invested $30B in Blue Origin since 2000, including $2B in its first outside funding round, which has raised $10B at a $140B valuation
A $10B outside round on a $140B valuation after $30B of founder capital is space as long-duration infrastructure, not a side bet. If your roadmap touches launch, in-orbit services, or space data, assume deep-pocketed platforms will set price and cadence, not smaller providers.
Startups & VentureStartup Spotlight: Marketing vets launch Kompeld to measure if a company’s story is actually working
Kompeld turning messaging clarity into a scored product is a sign that narrative quality is becoming a measurable, optimizable asset, not just a brand exercise. B2B teams should expect board and sales pressure for quantifiable story health alongside pipeline and NPS.
Startups & VentureSources: Jev developer TypeSafe is in talks to raise $1B+ at a $10B+ valuation; last week the startup announced a $40M seed, PitchBook says at a $200M valuation
A jump from a $200M seed to $10B+ in a week is less about fundamentals and more about capital’s fear of missing the next foundation layer. If you’re an operator, treat Jev as a high-volatility dependency—experiment, but don’t anchor roadmaps on a tool whose funding curve outpaces its production proof.